Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ABL1 T315I ABL1 R332W |
| Therapy | Imatinib |
| Indication/Tumor Type | lung adenocarcinoma |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ABL1 T315I ABL1 R332W | lung adenocarcinoma | resistant | Imatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Gleevec (imatinib) in culture and in xenograft models (PMID: 26758680). | 26758680 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (26758680) | Somatically mutated ABL1 is an actionable and essential NSCLC survival gene. | Full reference... |